Tecfidera Stands Out From The Pack Of 2013 Drug Launches
Executive Summary
Biogen Idec’s Tecfidera, on track to generate more than $1 billion in sales its first 12 months on the market, was the exceptional drug launch of 2013, in a year that included few breakout stars.
You may also be interested in...
10 Triumphant Drug Launches Of The Decade
The view from 2020: Scrip looks back at the most successful commercial launches of the decade.
Roche's Ocrevus: A Rare First-Year Blockbuster
Ocrevus generated roughly $935m in 2017 after launching in April, exceeding recent drug launches and putting the multiple sclerosis therapy in company with early successes like Opdivo, Ibrance, Tecfidera and Eylea.
With Anoro, GSK Takes A Two-Step Toward Bolstering Respiratory
FDA approved GSK’s Anoro Ellipta as the first LABA/LAMA combination product in the U.S. for the maintenance treatment of COPD Dec. 18, positioning GSK to launch a second respiratory product months after launching Breo Ellipta.